Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | ImpB/MucB/SamB family protein | 0.0074 | 0.2609 | 0.1936 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0834 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0086 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0045 | 0.0834 | 0.0086 |
Trypanosoma cruzi | phosphoglycerate kinase, putative | 0.0072 | 0.2497 | 0.1885 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0086 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0086 |
Trypanosoma brucei | unspecified product | 0.0045 | 0.0834 | 0.0834 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0834 |
Leishmania major | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0086 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0834 |
Trypanosoma cruzi | phosphoglycerate kinase, putative | 0.0072 | 0.2497 | 0.1885 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0834 |
Leishmania major | PAS-domain containing phosphoglycerate kinase, putative | 0.0072 | 0.2497 | 0.1885 |
Echinococcus multilocularis | dna polymerase eta | 0.0074 | 0.2609 | 0.1936 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0834 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0834 |
Trypanosoma brucei | phosphoglycerate kinase | 0.0072 | 0.2497 | 0.2497 |
Echinococcus granulosus | dna polymerase eta | 0.0074 | 0.2609 | 0.1936 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0045 | 0.0834 | 0.0834 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0045 | 0.0834 | 0.0834 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0045 | 0.0834 | 0.0834 |
Leishmania major | DNA polymerase eta, putative | 0.0074 | 0.2609 | 0.2005 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0834 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0834 |
Trypanosoma cruzi | PAS-domain containing phosphoglycerate kinase, putative | 0.0072 | 0.2497 | 0.1885 |
Trypanosoma cruzi | 3-phosphoglycerate kinase, glycosomal | 0.0072 | 0.2497 | 0.1885 |
Loa Loa (eye worm) | hypothetical protein | 0.0074 | 0.2609 | 0.1936 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0074 | 0.2609 | 0.2005 |
Brugia malayi | Phosphoglycerate kinase | 0.0072 | 0.2497 | 0.1814 |
Schistosoma mansoni | DNA polymerase eta | 0.0074 | 0.2609 | 0.1936 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0834 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0074 | 0.2609 | 0.2609 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0834 |
Trypanosoma cruzi | PAS-domain containing phosphoglycerate kinase, putative | 0.0072 | 0.2497 | 0.1885 |
Trypanosoma brucei | phosphoglycerate kinase, putative | 0.0072 | 0.2497 | 0.2497 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0045 | 0.0834 | 0.0086 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | < 40 % | Antiplasmodial activity against Plasmodium berghei infected in NMRI mice (Mus musculus) assessed as reduction of parasitaemia level at 10 mg/kg, perorally administered 1 day after post-infection measured after 3 days post-infection | ChEMBL. | 19924861 |
IC50 (functional) | = 2.1 ng/ml | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected in human A+ erythrocytes assessed as [3H]hypoxanthine incorporation by semi-automated micro dilution assay | ChEMBL. | 19924861 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 19924861 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.